Mark Roschewski

Mark Roschewski

UNVERIFIED PROFILE

Are you Mark Roschewski?   Register this Author

Register author
Mark Roschewski

Mark Roschewski

Publications by authors named "Mark Roschewski"

Are you Mark Roschewski?   Register this Author

55Publications

-Reads

Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.

Best Pract Res Clin Haematol 2018 Sep 3;31(3):285-292. Epub 2018 Jul 3.

Lymphoid Malignancies Branch, CCR, NCI, Building 10, Room 4N115, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address:

View Article
September 2018

End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams

Haematologica 2018 Aug;103(8):e382

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

View Article
August 2018

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2018 Aug 20:JCO2018785246. Epub 2018 Aug 20.

David M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander F.M. Craig, Mohammad Shahrokh Esfahani, Jacob J. Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron M. Newman, Maximilian Diehn, and Ash A. Alizadeh, Stanford University, Stanford, CA; Florian Scherer, University Medical Center Freiburg, Freiburg; Ulrich Dührsen and Andreas Hüttmann, University Hospital Essen, Essen, Germany; Michel Meignan, Hôpitaux Universitaires Henri Mondor, Creteil; René-Olivier Casasnovas, Hôpital Le Bocage, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski and Wyndham H. Wilson, National Cancer Institute, National Institutes of Health, Bethesda, MD; Gianluca Gaidano and Davide Rossi, University of Eastern Piedmont, Novara, Italy; and Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.

View Article
August 2018

Host-related immunodeficiency in the development of multiple myeloma.

Leuk Lymphoma 2018 May 9;59(5):1127-1132. Epub 2017 Aug 9.

b Myeloma Service, Department of Medicine , Memorial Sloan-Kettering Cancer Center , New York , NY, USA.

View Article
May 2018

What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R?

Br J Haematol 2018 Mar 13. Epub 2018 Mar 13.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article
March 2018

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.

Leuk Lymphoma 2018 02 22;59(2):505-508. Epub 2017 Jun 22.

b Lymphoid Malignancies Branch , Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.

View Article
February 2018

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

J Clin Oncol 2017 Jun 14;35(16):1803-1813. Epub 2017 Mar 14.

James N. Kochenderfer, Robert P.T. Somerville, Tangying Lu, Victoria Shi, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Constance M. Yuan, Mark J. Roschewski, Steven A. Feldman, Lori McIntyre, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD; Adrian Bot, John Rossi, Allen Xue, Marika Sherman, and Arianne Perez, Kite Pharma, Santa Monica, CA; Tatyana Feldman, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; and Jonathan W. Friedberg, University of Rochester School of Medicine, Rochester, NY.

View Article
June 2017

Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.

Curr Treat Options Oncol 2016 09;17(9):47

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bldg 10, Room 4N/115, Bethesda, MD, 20892, USA.

View Article
September 2016

Precision monitoring takes the stage.

Authors:
Mark Roschewski

Blood 2016 07;128(2):149-50

NATIONAL CANCER INSTITUTE.

View Article
July 2016

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.

Blood 2016 06 14;127(25):3127-32. Epub 2016 Apr 14.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article
June 2016

Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.

Haematologica 2016 Jan 30;101(1):e27-9. Epub 2015 Oct 30.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article
January 2016

Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors.

Leuk Lymphoma 2015 Jun;56(6):1583-4

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA.

View Article
June 2015

Monitoring lymphoma patients after therapy.

Authors:
Mark Roschewski

Clin Adv Hematol Oncol 2015 May;13(5):277-9

Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

View Article
May 2015

Cracking the diverse biologic code of diffuse large B-cell lymphoma.

Semin Hematol 2015 Apr 21;52(2):55-6. Epub 2015 Jan 21.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article
April 2015

Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.

Leuk Lymphoma 2014 Nov 7;55(11):2428-37. Epub 2014 Mar 7.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA.

View Article
November 2014

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Cytokine 2014 Oct 17;69(2):294-7. Epub 2014 Jul 17.

Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article
October 2014

Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.

Clin Cancer Res 2014 Oct;20(20):5182-93

Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, Maryland.

View Article
October 2014

Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.

J Clin Oncol 2014 Sep 14;32(25):2699-704. Epub 2014 Jul 14.

Brendan M. Weiss, University of Pennsylvania, Philadelphia, PA; Joseph Hebreo, Naval Medical Center San Diego, San Diego, CA; Daniel V. Cordaro, Mark J. Roschewski, Thomas Baker, Kevin C. Abbott, and Stephen W. Olson, Walter Reed National Military Medical Center, Bethesda, MD.

View Article
September 2014

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.

Leuk Lymphoma 2014 Aug 24;55(8):1707-14. Epub 2014 Jan 24.

Multiple Myeloma Section, Metabolism Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD , USA.

View Article
August 2014

Intraocular (vitreoretinal) lymphoma with renal, pelvic, and central nervous system lesions.

Can J Ophthalmol 2014 Aug 17;49(4):e104-6. Epub 2014 Jul 17.

National Eye Institute, National Institutes of Health, Bethesda, Md. Electronic address:

View Article
August 2014

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Haematologica 2014 Jun 21;99(6):e81-3. Epub 2014 Mar 21.

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

View Article
June 2014

Minimal residual disease: what are the minimum requirements?

J Clin Oncol 2014 Feb 13;32(5):475-6. Epub 2014 Jan 13.

Center for Cancer Research, National Institutes of Health, Bethesda, MD.

View Article
February 2014

Smoldering multiple myeloma: present position and potential promises.

Eur J Haematol 2014 Jan 26;92(1):1-12. Epub 2013 Nov 26.

Multiple Myeloma Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article
January 2014

Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Nat Rev Clin Oncol 2014 Jan 12;11(1):12-23. Epub 2013 Nov 12.

Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10 Room 4N115, Bethesda, MD 20892, USA.

View Article
January 2014

Pursuing the curative blueprint for early myeloma.

Blood 2013 Jul 19;122(4):486-90. Epub 2013 Jun 19.

Multiple Myeloma Section, Center for Cancer Research, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
July 2013

Lymphomatoid granulomatosis.

Cancer J 2012 Sep-Oct;18(5):469-74

Hematologic Malignancy Section, Walter Reed National Military Medical Center, Bethesda, MD 20892, USA.

View Article
April 2013

Evolving therapeutic paradigms for multiple myeloma: back to the future.

Leuk Lymphoma 2013 Mar 14;54(3):451-63. Epub 2012 Sep 14.

Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
March 2013

Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.

Am J Hematol 2013 Feb 21;88(2):89-92. Epub 2012 Nov 21.

Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article
February 2013

CD5+ diffuse large B-cell lymphoma with hemophagocytosis.

J Clin Oncol 2013 Feb 26;31(6):e76-9. Epub 2012 Nov 26.

Department of Hematology/Oncology, Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA.

View Article
February 2013

Diffuse large B cell lymphoma: molecular targeted therapy.

Int J Hematol 2012 Nov 20;96(5):552-61. Epub 2012 Oct 20.

Lymphoma Therapeutics Section, Metabolism Branch, National Cancer Institute, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.

View Article
November 2012

Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes.

Curr Hematol Malig Rep 2012 Sep;7(3):208-15

Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article
September 2012

EBV-associated lymphomas in adults.

Best Pract Res Clin Haematol 2012 Mar 5;25(1):75-89. Epub 2012 Feb 5.

Walter Reed National Military Medical Center, Bethesda, MD 20814, USA.

View Article
March 2012

Nodal marginal zone lymphoma: impersonalized medicine.

Oncology (Williston Park) 2012 Jan;26(1):104, 106, 108

Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, Maryland, USA.

View Article
January 2012

Multiple myeloma with lacrimal gland amyloidosis and sarcoidosis.

Am J Hematol 2010 Jul;85(7):506-9

Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307, USA.

View Article
July 2010

Biology and management of rare primary extranodal T-cell lymphomas.

Oncology (Williston Park) 2010 Jan;24(1):94-100

Walter Reed Army Medical Center Washington, DC, USA.

View Article
January 2010